Skip to main content
Premium Trial:

Request an Annual Quote

Caprion Licenses Antibody Technologies, Therapeutic Antibodies from Sunol Molecular

NEW YORK, June 7 (GenomeWeb News) - Caprion Pharmaceuticals has acquired humanized monoclonal antibody technologies as well as therapeutic antibodies from Miramar, Fla.-based Sunol Molecular, the company said today.

 

Caprion, based in Montreal, plans to apply the antibody technologies to develop therapeutics against tumor antigens it discovered using its proteomic profiling technology. Initially, the company will focus on solid tumors.

 

The therapeutic antibodies, which are currently in phase I clinical trials, are being developed to treat Hemolytic Uremic Syndrome resulting from E. coli infection.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.